Skip to main content

Title of Proposal: Restoring the immune system homeostasis and organ function in severe community acquired pneumonia- induced sepsis through adipose derived allogeneic stem cells (SEPCELL Proje

Objective

Sepsis is defined as a systemic inflammatory response to infection, while severe sepsis (SS) is a sepsis complicated by acute organ dysfunction. Lung infections, in particular community-acquire pneumonia (CAP), are the leading cause of SS. The pathophysiologic mechanism of CAP-mediated SS is the complete dysregulation of the patient´s immune system. In an initial phase, the systemic hyperactivation of the host immune response against infection leads to high levels of inflammatory mediators, systemic vasodilatation, micro-vascular thrombosis and organ failure. In a second phase, the exaggerated activation of the immune response leads to a state of ‘immunoparalysis’, which is characterized by the occurrence of secondary, opportunistic infections. This makes CAP-mediated SS a life-threatening condition with mortality rates as high as 28-50%. The current standard of care (infection removal and control, functional support) does not improve the high mortality and, thus, CAP-mediated SS represents a major unmet medical need with a huge social burden. Therefore, treatments with the potential to modulate both the initial exacerbated immunoactivation and the subsequent immunosuppression are needed. Mesenchymal stem cells (MSCs), including adipose mesenchymal stem cells (ASCs), are known for their broad range of immunomodulatory properties, targeting multiple pro- and anti-inflammatory pathways, and possess antimicrobial capacities (releasing bactericidal peptides and promoting the phagocytosis by immune cells). Indeed, therapeutic benefit of MSC treatment in in vivo experimental models of sepsis has been extensively reported. The SEPCELL consortium believes that cell therapy with allogeneic ASCs may be an innovative therapeutic approach in order to re-establish the normal immune homeostasis of CAP-mediated SS patients, reducing organ injury and restoring organ functionality. A phase Ia/IIb clinical trial will be performed to test this possibility.

Field of science

  • /medical and health sciences/medical biotechnology/cells technologies/stem cells
  • /medical and health sciences/basic medicine/physiology/homeostasis
  • /social sciences/sociology/demography/mortality
  • /medical and health sciences/basic medicine/immunology

Call for proposal

H2020-PHC-2015-single-stage_RTD
See other projects for this call

Funding Scheme

RIA - Research and Innovation action

Coordinator

TIGENIX SA
Address
Calle Marconi 1
28760 Tres Cantons
Spain
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
EU contribution
€ 995 245

Participants (5)

Centre hospitalier universitaire de Limoges
France
EU contribution
€ 2 179 500
Address
Avenue Martin-luther-king 2
87000 Limoges
Activity type
Research Organisations
CLINIQUES UNIVERSITAIRES SAINT-LUC
Belgium
EU contribution
€ 534 375
Address
Avenue Hippocrate 10
1200 Bruxelles
Activity type
Research Organisations
ACADEMISCH MEDISCH CENTRUM BIJ DE UNIVERSITEIT VAN AMSTERDAM
Netherlands
EU contribution
€ 1 071 790
Address
Meibergdreef 15
1105AZ Amsterdam
Activity type
Higher or Secondary Education Establishments
SERVICIO MADRILENO DE SALUD
Spain
EU contribution
€ 297 678,50
Address
Plaza Carlos Trias Bertran 7
28020 Madrid
Activity type
Public bodies (excluding Research Organisations and Secondary or Higher Education Establishments)
TiGENIX NV
Belgium
EU contribution
€ 291 297,50
Address
Researchpark Haasrode 1724 Romeinse Straat 12/2
3001 Leuven
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)